AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD [Seeking Alpha]
AC Immune SA (ACIU)
Last ac immune sa earnings: 11/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acimmune.com/en/investors
Company Research
Source: Seeking Alpha
AC Immune is advancing ACI-7104.056, with upcoming FDA discussions to potentially establish a registration study as a key value-driving catalyst. The company benefits from a robust pipeline, including partnerships with Takeda and Johnson & Johnson, and significant milestone opportunities. Final data from Part 1 of the VacSYn trial is expected mid-2026, providing further clinical and regulatory catalysts. 24K-Production/iStock via Getty Images The last time I spoke about AC Immune ( ACIU ), it was with respect to a Seeking Alpha article entitled " AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward ". With respect to More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive a
Show less
Read more
Impact Snapshot
Event Time:
ACIU
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACIU alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACIU alerts
High impacting AC Immune SA news events
Weekly update
A roundup of the hottest topics
ACIU
News
- AC Immune posts positive data for Parkinson's immunotherapy [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease [Yahoo! Finance]Yahoo! Finance
- AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s DiseaseGlobeNewswire
- AC Immune to Present at the Jefferies 2025 London Healthcare ConferenceGlobeNewswire
- AC Immune (NASDAQ:ACIU) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.MarketBeat
ACIU
Earnings
- 11/4/25 - Beat
ACIU
Sec Filings
- 12/11/25 - Form 6-K
- 11/4/25 - Form 6-K
- 10/3/25 - Form 144
- ACIU's page on the SEC website